Adamis Pharma Executives

ADMPDelisted Stock  USD 0.56  0.02  3.45%   
Adamis Pharma employs about 11 people. The company is managed by 14 executives with a total tenure of roughly 120 years, averaging almost 8.0 years of service per executive, having 0.79 employees per reported executive. Discussion of Adamis Pharma's management performance can provide insight into the enterprise performance.
Dennis Carlo  CEO
CEO and President and Director
Robert Rothermel  Chairman
Consultant, Director, Chairman of Audit Committee, Member of Nominating and Governance Committee and Member of Compensation Committee
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Adamis Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (1.045) % which means that it has lost $1.045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.8496) %, meaning that it created substantial loss on money invested by shareholders. Adamis Pharma's management efficiency ratios could be used to measure how well Adamis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Adamis Pharma Workforce Comparison

Adamis Pharma is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 23,936. Adamis Pharma adds roughly 11.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Adamis Pharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adamis Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adamis Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Adamis Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Adamis Pharma Notable Stakeholders

An Adamis Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Adamis Pharma often face trade-offs trying to please all of them. Adamis Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Adamis Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dennis CarloCEO and President and DirectorProfile
Robert RothermelConsultant, Director, Chairman of Audit Committee, Member of Nominating and Governance Committee and Member of Compensation CommitteeProfile
Richard WilliamsChairman, Consultant, Chairman of Compensation Committee, Member of Audit Committee and Member of Nominating and Governance CommitteeProfile
Thomas MollVice President - ResearchProfile
Gus FernandezVice President - Commercial OperationsProfile
Robert HopkinsCFO, VP of Fin. and SecretaryProfile
David MarguglioSr. VP of Corporate Devel. and DirectorProfile
William DenbyIndependent DirectorProfile
Karen DanielsVP of OperationsProfile
Mark GundyIR Contact OfficerProfile
Jennifer SuskiDirector MarketingProfile
Eddie GloverChief IncProfile
Mark FlatherIR Contact OfficerProfile
David BenedictoChief OfficerProfile

About Adamis Pharma Management Performance

The success or failure of an entity such as Adamis Pharma often depends on how effective the management is. Adamis Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Adamis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Adamis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California. Adamis Pharmaceuticl operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
The data published in Adamis Pharma's official financial statements usually reflect Adamis Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Adamis Pharma. For example, before you start analyzing numbers published by Adamis accountants, it's critical to develop an understanding of what Adamis Pharma's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Adamis Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adamis Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Adamis Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adamis Pharma. Please utilize our Beneish M Score to check the likelihood of Adamis Pharma's management manipulating its earnings.

Adamis Pharma Workforce Analysis

Traditionally, organizations such as Adamis Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Adamis Pharma within its industry.

Adamis Pharma Manpower Efficiency

Return on Adamis Pharma Manpower

Revenue Per Employee432.4K
Revenue Per Executive339.7K
Net Loss Per Employee2.4M
Net Loss Per Executive1.9M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Consideration for investing in Adamis Stock

If you are still planning to invest in Adamis Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adamis Pharma's history and understand the potential risks before investing.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios